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Abstract
The inflammasome is a proteolysis complex that generates the active forms of the pro-
inflammatory cytokines IL-1β and IL-18. Inflammasome activtation is mediated by NLR proteins
that respond to microbial and nonmicrobial stimuli. Among NLRs, NLRP3 senses the widest array
of stimuli and enhances adaptive immunity. However, its role in antitumor immunity is unknown.
Therefore, we evaluated the function of the NLRP3 inflammasome in the immune response using
dendritic cell vaccination against the poorly immunogenic melanoma cell line B16-F10.
Vaccination of Nlrp3−/− mice led to a relative 4-fold improvement in survival relative to control
animals. Immunity depended upon CD8+ T cells and exhibited immune specificity and memory.
Increased vaccine efficacy in Nlrp3−/− hosts did not reflect differences in dendritic cells but rather
differences in myeloid-derived suppressor cells (MDSCs). Although Nlrp3 was expressed in
MDSCs, the absence of Nlrp3 did not alter either their functional capacity to inhibit T cells or their
presence in peripheral lymphoid tissues. Instead, the absence of Nlrp3 caused a 5-fold reduction in
the number of tumor-associated MDSCs found in host mice. Adoptive transfer experiments also
showed that Nlrp3−/− MDSCs were less efficient in reaching the tumor site. Depleting MDSCs
with an anti-Gr-1 antibody increased the survival of tumor-bearing wild-type mice but not
Nlrp3−/− mice. We concluded that Nlrp3 was critical for accumulation of MDSCs in tumors and
for inhibition of antitumor T cell immunity after dendritic cell vaccination. Our findings establish
an unexpected role for Nlrp3 in impeding antitumor immune responses, suggesting novel
approaches to improve the response to antitumor vaccines by limiting Nlrp3 signaling.
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NLR family, pyrin domain containing 3 (Nlrp3) is a member of the nucleotide-binding
domain and leucine-rich repeat containing gene family of intracellular sensors. When
activated, Nlrp3 forms a protein complex called the inflammasome (1–3). The
inflammasome combines Nlrp3 with the adaptor molecule ASC/PYCARD/TMS/CARD5,
Cardinal, and pro-caspase-1 (4) to form a multimer. The result is the proteolytic maturation
of caspase-1, which cleaves and activates proIL-1β and proIL-18 to generate IL-1β and
IL-18 (3).
Nlrp3 senses a variety of microbial and nonmicrobial molecular motifs. The microbial
signals are part of the pathogen associated molecular patterns or PAMPs and include gram
positive and negative bacteria, RNA and DNA viruses, polyinosinic:polycytidylic acid, and
LPS (1). The nonmicrobial signals include exogenous compounds such as asbestos and
endogenous signals such as urate crystals (1). Many of these nonmicrobial stimuli are
referred to as damage associated molecular patterns or DAMPs (5). Activation by these
signals not only promotes innate immunity but also enhances Th1, Th2 and Th17 responses
(6). Thus, the inflammasome responds to many pathological insults and participates in
multiple immune pathways (7).
In contrast to this literature on PAMPs and DAMPs, there have been few studies
characterizing Nlrp3 in the tumor microenvironment though stimuli for its activation are no
doubt present (8). However, studies on Il-1β suggest a potential tumor promoting role in
several mouse models (9–10). Conversely, reduction of IL-1β diminished metastases to the
lung (11) and eliminating IL-1β prevented progression in a murine melanoma model (12).
Human studies have been less definitive but remain consistent with the murine data. For
example, gastric cancer is associated with genetic polymorphisms linked to enhanced IL-1β
expression (13). Similar studies on IL-18 polymorphisms have demonstrated an increased
risk for other epithelial cancers (14). More directly, serum IL-18 concentrations are
inversely correlated with survival in hepatocellular cancer (15).
These cytokines can contribute to tumorigenesis in several ways though more recent
attention has focused on their role in promoting myeloid-derived suppressor cells (MDSCs)
(16–17). MDSCs are a heterogeneous population of immature myeloid cells that are most
readily identified in the mouse by their expression of Gr-1 and CD11b (18). These cells
suppress T cell responses directly by a variety of mechanisms (19). MDSCs also contribute
to tumorigenesis indirectly by inducing regulatory T cells (20) and a Th2 immune response
(21), suppressing NK cells (22), and increasing angiogenesis (23). Clinical studies have
documented these cells in several human cancers (24) including head and neck (25), renal
cell (26), and hepatocellular (22) cancers. Both murine and human studies have found the
number of MDSCs increases with tumor burden (24,27).
These data suggest Nlrp3 activation could inhibit the antitumor immune response to a cancer
vaccine by enhancing the function of immunosuppressive cells. We were led to test this
hypothesis after completing gene array studies that showed an association between Nlrp3
and MDSCs.
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Nlrp3−/− mice were generated as described (28). EGFP X Nlrp3−/− transgenic mice were
produced by crossing F1 progeny of EGFP transgenic and homozygous Nlrp3−/− mice. All
other mice were purchased from Jackson Laboratories. All experiments were conducted
using protocols approved by Institutional Animal Care and Use Committee of the University
of North Carolina at Chapel Hill.
Dendritic Cell Vaccination Model
Tumor lines were purchased from the American Type Culture Collection and were expanded
by six passages in 7.5% FCS/DMEM (Gibco). B16-F10 cells were authenticated by the
presence of melanin. Subcutaneous tumors were formed by injecting either 1×104 cells
(B16-F10, Lewis Lung) or 5×105 cells (E.G7-OVA) in the left leg. The leg diameter was
measured three times a week. Mice were euthanized when this diameter was > 6 mm and the
survival time was interpolated from the last two measurements. A tumor was designated as
“non-palpable” if the left leg diameter was within 0.2mm of the right leg and the tumor was
visible on gross dissection.
DCs were generated from bone marrow cultures treated with GM-CSF and IL-4 (Peprotech
Inc) (29). DCs were pulsed at an 8:1 ratio with B16-F10 lysates formed by irradiation
(16,000 rads), five rounds of freeze/thaw, and shearing by a 30 gauge needle. After antigen
pulsing, DCs were matured with 100 ng/ml of LPS for 24 hours. 1×106 cells were
subcutaneously injected on day three and ten after tumor injection.
Cell depletion was accomplished by the intraperitoneal injection of 200 mcg of PK136 (NK
cell) and RB6-8C5 (MDSC) and 500 mcg of 53.6.72 (CD8 T cell) and GK1.5 (CD4 T cell)
mAb (BioExpress). The injection schedule for lymphoid cell depletion was day -1, day 0
and then biweekly. MDSC depletion injections were biweekly starting on day 6.
Flow Cytometry
Flow cytometry was performed as previously described (30). For the migration assays,
MDSCs were harvested from the spleens of EGFP transgenic C57BL/6 or Nlrp3−/− mice by
immunomagnetic bead separation (Miltenyi) two weeks after intravenous tumor injection.
These cells were then cryopreserved. Nlrp3−/− mice were injected with 25,000 B16-F10
cells while WT received 1×104. When the tumor was palpable, the mice received an
intravenous injection of 5×105 EGFP MDSCs. Three days after this injection, the tumor was
harvested, digested, and processed flow cytometry.
MDSC Assay
MDSCs for the in vitro suppression assays were harvested by FACS sorting from the lungs
of WT and Nlrp3−/− mice two weeks after intravenous injection with 1×106 B16-F10 cells.
Immunosuppression was evaluated by adding these cells to a MLR. Stimulator cells were
taken from the adherent fraction of BALB/cJ splenocytes after two hours of culture;
responder cells were harvested from the non-adherent fraction of C57BL/6J splenocytes.
Stimulators and CD11b+ Gr-1+ cells were treated with mitomycin C and responders were
labeled with CFSE.
Real time PCR
Total RNA was isolated from sorted cells using RNeasy columns (Qiagen) and converted to
cDNA with random hexamers and MMLV Reverse Transcriptase (Invitrogen). PCR
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amplification was performed using Nlrp3 specific primers and probe: 5′-
CTCCCGCATCTCCATTTGT-3′, 5′-GCGTGTAGCGACTGTTGA-3′, and FAM-
CCACACTCTCACCTAGACGCGC-TAMRA with TaqMan PCR reagents and 7900HT
Thermocycler (Applied Biosystems). Expression values were normalized to cell number.
Statistics
Data are reported as a mean ± standard error of the mean (SEM). Results were considered
significant if p ≤ 0.05 as determined by the Mann Whitney test. Comparisons in survival
were done by the Cox proportional hazard regression method
Results
The Nlrp3 is expressed in myeloid derived suppressor cells (MDSCs)
We have previously shown peripheral tolerance mechanisms are a major impediment to
successful anti-tumor vaccines in the FVB/neu mouse (31). In order to delineate
mechanisms by which MDSCs function in this model, we utilized Affymetrix whole mouse
genome arrays to compare gene expression from Gr-1+, CD11b+ MDSCs isolated from the
spleen with those from the tumor. This experiment revealed that 16 genes were upregulated
by more than threefold in the tumor-associated MDSCs (Supplementary Table S1). Of these
16 genes, Nlrp3 and Il-1β were substantially increased in expression (Nlrp3 11.9 ± 3.2 fold;
Il-1β 3.85 ± 0.7 fold) in the tumor environment. These results suggested activation of the
Nlrp3 inflammasome occurs in MDSCs present in the tumor microenvironment.
We tested the role of the Nlrp3 inflammasome more directly using the B16-F10 tumor and
B6 mice whose background would allow us to compare wild type (WT) with Nlrp3−/− mice.
First, we verified the expression of Nlrp3 in the tumor-associated Gr-1+, CD11b+ cells,
which had been isolated by cell sorting. Both Gr-1+, CD11b+ and Gr-1−, CD11b+ cells
expressed Nlrp3 at transcript numbers significantly greater than found in CD11b− cells (4.30
± 0.13, 4.69 ± 0.94 vs. 0.00 ± 0.0, p = 0.033) (Fig. 1A). Nlrp3 was not expressed in Nlrp3−/−
mice (Fig. 1B).
Dendritic cell vaccination improves survival in Nlrp3−/− mice
We then compared the survival of WT and Nlrp3−/− mice that received a subcutaneous
injection of 1×104 B16-F10 melanoma cells. In this model, none of the WT or Nlrp3−/−
mice survived (Fig. 2A). The median survival was also not significantly different (15.3 vs.
16.6 days, p = NS).
The survival of Nlrp3−/− mice could be improved by administering a DC vaccine on days 3
and 10 after tumor injection. In these experiments, mice received inoculations of 1×106 WT
DCs pulsed with B16-F10 tumor cell lysate. Although only 9.1% of the WT mice
demonstrated long term survival, survival in the Nlrp3−/− mice increased to 35%. The
hazard ratio favoring survival in the Nlrp3−/− mice was 2.4 (1.2 – 4.8) (p = 0.017) (Fig. 2B).
The survival benefit was not limited to the B16-F10 model. WT and Nlrp3−/− mice were
also subcutaneously injected with 5×105 E.G7-OVA tumor cells and then treated with
peptide pulsed DCs using the same schedule. As before, Nlrp3−/− mice had a substantial
improvement in survival compared to WT mice (33.3% vs. 62.5%). The hazard ratio
favoring survival in the Nlrp3−/− mice was 2.1 (1.6 – 3.1) (p = 0.023) (Supplementary Fig.
S1).
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Nlrp3 expression by the host limits the effectiveness of the DC vaccine
Since this survival advantage may have been dependent on the expression of Nlrp3 by the
DCs, we compared survival in Nlrp3−/− mice treated with DC vaccines from WT or
Nlrp3−/− mice. Thirty three percent of the Nlrp3−/− mice injected with Nlrp3−/− DC vaccine
survived compared to 40% injected with the WT vaccine (p = NS) (Fig. 2C). Thus, the
Nlrp3−/− DC vaccine produced survival that was comparable to WT vaccines in Nlrp3−/−
mice.
Subsequently, we evaluated the effectiveness of vaccination using Nlrp3−/− and WT DCs in
WT mice. None of the WT mice survived. Those receiving the WT vaccine had a median
survival of 21.8 days versus 16.1 days with the Nlrp3−/− vaccine (p=NS) (Fig. 2D). From
these data, we concluded the poor outcome in WT mice was due to Nlrp3 expression by host
cells and not by the cells given with the vaccine.
The benefit of the DC vaccine in Nlrp3−/− mice is CD8 dependent
The immunologic memory of the vaccinated Nlrp3−/− mice was tested by rechallenging
these mice three months after their initial tumor exposure. Ten of the eleven rechallenged
Nlrp3−/− mice survived a second tumor injection (90.9%) (Fig. 3A). Two of the surviving
WT mice were also rechallenged and one survived (50%). Due to the low number of
surviving WT mice, we were unable to establish statistical significance. Nevertheless, these
experiments demonstrated an antitumor memory response in the Nlrp3−/− mice and implied
the improved outcome was due to an enhanced immune response to the vaccine.
The specificity of this tumor protection was examined by challenging surviving Nlrp3−/−
mice with an unrelated tumor. Eight Nlrp3−/− mice received 1×104 Lewis lung carcinoma
cells (LLCa) and two mice survived (25%) (Fig. 3A). This result was significantly less than
those rechallenged with B16-F10 cells (p = 0.003) but not different from naive Nlrp3−/−
mice injected LLCa cells (survival = 20%). Therefore, the immunological memory
generated after vaccination in Nlrp3−/− mice was specific only for the tumor used in the
vaccine.
The efficacy of the adaptive immune response was further tested by measuring survival after
antibody depletion of CD4+, CD8+, or NK cells (Supplementary Fig. S2). The effect of cell
depletion was measured by calculating a hazard ratio using Cox regression analysis. The
survival of all three cohorts of cell-depleted Nlrp3−/− mice was decreased compared to the
control Nlrp3−/− mice (Fig. 3B, C). However, this finding was only statistically significant
for Nlrp3−/− mice after the depletion of CD8+ T cells (HR = 2.06, p = 0.028). Therefore, the
enhanced activity of tumor vaccination in the Nlrp3 −/− mice required CD8+ T cells.
This conclusion was supported by determining the number of CD8 effector T cells from the
lymph nodes of DC vaccinated mice. Tumor-draining nodes were harvested on day 14
following DC vaccinations on day 3 and 10. The number of CD62Llo, CD69hi effector cells
was measured by flow cytometry. There were no differences in the number of CD8 effector
cells between WT and Nlrp3−/− mice either with or without tumor injection. However,
differences became apparent when the tumor injected mice were further subdivided into
groups with palpable or non-palpable tumors. Using this analysis, Nlrp3−/− mice with no
palpable tumor had significantly more CD8 effector cells than WT mice (18.1 ± 0.4 vs.3.5 ±
0.5 ×104 cells, p = 0.002) (Fig. 3D). There were no differences in the number of CD4
effectors or in the number of CD8+ cells in mice with palpable tumors.
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Nlrp3−/− MDSCs are morphologically and functionally equivalent to WT MDSCs in vitro
Given this result, we compared the microscopic appearance and the functional activity of
MDSCs from Nlrp3−/− and WT tumor-bearing mice. Tumor-associated MDSCs from both
mice could be further divided into two subpopulations based on their expression of Gr-1 and
CD11b. The Gr-1Hi, CD11b+ cells had a neutrophil morphology and the Gr-1Int, CD11b+
cells had a monocytic morphology. These subpopulations corresponded to the granulocytic
and monocytic MDSCs described by Youn et al. (32). However, there were no microscopic
differences between Nlrp3−/− or WT MDSCs within each subpopulation (Fig. 4A).
Since the numbers of MDSCs within the tumors were inadequate for in vitro suppression
assays, we isolated these cells from the lungs of WT and Nlrp3−/− mice with B16-F10
metastasis. Once again, two subpopulations of MDSCs could be identified by CD11b and
Gr-1 expression. The monocytic MDSCs displayed a greater suppressive capacity compared
to the granulocytic MDSCs. However, we did not find differences in T cell suppression
between WT and Nlrp3−/− MDSCs from either subpopulation (Fig. 4B). There were also no
differences in the suppressive ability of MDSCs isolated from the spleens of WT and
Nlrp3−/− mice with metastatic melanoma after DC vaccination (Supplementary Fig. S3).
Regardless of the differences among Gr-1Hi and Gr-1Int MDSCs, the central observation
from these experiments was no differences were detected when comparing cells from WT
and Nlrp3−/− mice. These data indicate the disparity in the vaccine response between the
WT and Nlrp3−/− mice was not due to differences in the suppressive capacity of their
respective MDSCs.
Nlrp3−/− mice have fewer MDSCs at the tumor site
Since the survival advantage of the Nlrp3−/− mouse could not be explained by functional
differences in MDSCs, we hypothesized this advantage was due to a reduction in the number
of MDSCs. We found no significant differences in the number of Gr-1+, CD11b+ cells
isolated from tumor draining lymph node (TDLN) 14 days after tumor injection (Fig 5A).
There was a trend to a lower percentage of splenic MDSCs in the Nlrp3−/− mice but this
finding was not statistically significant (1.61 ± 0.24% vs. 2.67 ± 0.40%, p = 0.11) (Fig. 5A).
We next evaluated the number of MDSCs within the tumor by immunofluorescent
microscopy. Mice were included in this analysis if their tumor was visible by light
microscopy. This approach revealed a five fold increase in the number of CD11b/Gr-1+ cells
in the tumor and surrounding stroma of WT mice compared to Nlrp3−/− mice (18.6 ± 3.0/
LPF vs. 3.5 ± 0.5/LPF, p = 0.02) (Fig. 5B, Supplementary Fig. S4).
Since immunohistochemistry cannot distinguish between Gr-1Hi and Gr-1Int cells, the
percentage of these two populations was measured using flow cytometry. Tumors were
harvested when palpable; mice without tumor were excluded. Gating on the Gr-1Int, CD11b+
cells revealed a 4.7 fold increase of the monocytic MDSCs in WT mice compared to
Nlrp3−/− mice (2.1 ± 0.5% vs. 0.45 ± 0.24%, p = 0.003), while a six fold increase was noted
in the granulocytic MDSCs (0.54 ± 0.18% vs. 0.09%, p = 0.003) (Fig. 5C). Thus, both flow
cytometry and immunohistochemistry demonstrated a significant reduction in the number of
tumor-associated MDSCs in Nlrp3−/− compared to WT mice.
Depletion of MDSCs improves survival in vaccinated WT but not Nlrp3−/− mice
We established that the decrease in MDSCs accounted for the improved survival in Nlrp3−/−
mice by measuring survival following MDSC depletion. Anti-Gr-1 antibody was injected
twice a week beginning on day six. This treatment produced a 2.6 fold decrease in MDSCs
(Supplementary Fig. S5). Depletion of MDSCs eliminated the survival advantage of the
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vaccinated Nlrp3−/− mice over WT mice (HR = 1.15, p = 0.75) (Fig. 5D). This change was
exclusively due to an improvement in overall survival in the WT mice from 9.1% to 38.9%
(HR = 2.06, p <0.05). There was no difference in overall survival of the vaccinated
Nlrp3−/− mice after MDSC depletion (40.0% vs. 35.0%, p = 0.82). As a control, we
measured survival in unvaccinated WT and -Nlrp3−/− following MDSC depletion. Survival
was not significantly different from unvaccinated mice without MDSC depletion
(Supplementary Fig. S6). Together, these results strongly suggested the decreased number of
tumor-associated MDSCs accounted for the increased efficacy of the DC vaccine in
Nlrp3−/− mice.
Nlrp3 expression promotes migration of MDSCs into the tumor
We assessed the effect of Nlrp3 on migration by isolating splenic MDSCs from WT and
Nlrp3−/− mice and then transferring those cells to Nlrp3−/− mice with subcutaneous tumors.
A population of MDSCs with greater than 90% purity could be effectively isolated with
proper titration of the Gr-1 antibody and immunomagnetic bead selection (Supplementary
Fig. S7). Furthermore, there were no differences in percentages of the subpopulations
between WT and Nlrp3−/− cells (Fig. 5E).
This approach revealed significantly fewer Nlrp3−/− MDSCs migrated into the tumor
compared to WT MDSCs (178.1 ± 91.0 cells/tumor vs. 448.0 ± 36.1 cells/tumor, p < 0.05)
(Fig. 5E). These results were not biased by tumor size since no difference in tumor size was
detected at the time of injection (4.1 ± 0.06 mm vs. 4.2 ± 0.25 mm. p = NS).
Discussion
DC vaccines represent a promising therapy for cancer; however, their efficacy is frequently
suboptimal. For example, a recent prostate cancer vaccine trial found treatment resulted in a
superior outcome, but the improvement in median survival was only 4.1 months (33). The
very modest efficacy of DC vaccination was substantiated in our model by the vaccine’s
inability to improve survival in WT mice. However, we found the efficacy of DC
vaccination could be markedly improved in the absence of Nlrp3.
The effect of Nlrp3 in the tumor environment was unanticipated because the established
signals for inflammasome priming and activation are not present. Our results and those of
others suggest this concept is changing. Li et al. have shown the Nlrp3 inflammasome can
be activated in a sterile setting by necrotic cancer cells (35). Priming is accomplished by an
excess of extra-cellular matrix components and activation is completed by ATP released
from dying cancer cells (36). These observations required either the administration of 1×107
pressurized cells (37) or chemotherapy (36). Our work extends these ideas to the activation
of Nlrp3 in the DC vaccine setting.
Further analysis implicated differences in MDSC number as the reason for the survival
advantage in vaccinated Nlrp3−/− mice. Nlrp3 does not appear to affect the ability of
MDSCs to suppress T cells. Instead, the reduction in quantity of MDSCs resulted in an
inhibition of cytotoxic CD8+ T cells and prompted a more effective antitumor response.
Our interpretation also explains why the administration of anti-Gr-1 antibodies restored the
efficacy of the vaccine in WT mice to a degree comparable with Nlrp3−/− mice. Antibody
depletion of Gr-1+ cells is well established in the literature (35,38–41) though the effect of
this depletion has had mixed results in cancer models (43). Improvement in anti-tumor
immunity has been documented in models using UV light-induced tumors (42), liver
carcinoma (35) and 15–12RM sarcoma cells (39). Our paper also demonstrates improvement
in WT mice and is the first to do so using a DC vaccine. On the other hand, injection with
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the Gr-1 antibody inhibited the immune response to a colon cancer cell line (38) and a NK
sensitive lymphoma (40). These differences reflect the functional heterogeneity of MDSCs
that is in part due to the tumor model used (43).
Though WT MDSCs were 2.5 times more efficient in migrating to the tumor, we did not
find differences in the number of MDSCs in the TDLN. This finding suggests MDSCs are
mobilized to the lymph node independently of Nlrp3. We believe mobilization to the spleen
is also Nlrp3 independent since lower number of splenic Nlrp3−/− MDSCs correlated with
tumor size. This observation suggests a critically important role for Nlrp3 in the recruitment
of MDSCs solely to the tumor microenvironment.
It is conceivable that the differences in the number of MDSCs present at the site of tumor
growth are due to changes in proliferation or survival. We believe our explanation of a role
for Nlrp3 in MDSC migration is more consistent with the literature. Nlrp3 is more likely to
induce cell death than cell survival. This effect has been documented in monocytes (47).
Furthermore, Nlrp3−/− myeloid cells are resistant to cell death induced by bacterial
pathogens (28). Wild type MDSCs are also not likely to have a proliferative advantage over
Nlrp3−/− cells. MDSC expansion appears to take place in niches distant from the tumor in
the spleen, bone marrow, and liver (48,49). The modest difference in the number of MDSCs
in the spleen is not compatible with the significantly different numbers of MDSCs at the
tumor site and strongly argues against proliferation as the sole reason for differences in
tumor-associated MDSC number.
Though the improvement in the response to the DC vaccine is encouraging, a majority of
tumors continue to grow even in Nlrp3−/− vaccinated mice. This finding is not particularly
surprising since there are no vaccine-only strategies that have consistently eliminated
established B16 F10 tumors (50). Though other forms of immune escape may also be at
work, we are particularly intrigued by the significant contribution of the Nlrp3
inflammasome, given the presence of Nlrp3 independent inflammasomes. For example,
inflammasomes containing absent in melanoma 2 (AIM2) (51) and ice protease-activating
factor (Ipaf), contribute to IL-1β production independent of Nlrp3. An even greater anti-
tumor response might be seen with inhibition of apoptosis-associated speck-like protein
containing a CARD (ASC) since ASC is common to multiple inflammasomes. Those studies
are underway in our laboratory.
At first glance, our result stands in contrast to recent findings that Nlrp3 might enhance
adaptive immunity. For example, Ghiringhelli et al. demonstrated the Nlrp3 inflammasome
was critically important in the P2X7R-dependent activation of DCs to generate IFN-γ
producing CD8+ T cells (36). As previously mentioned, this was mediated by the release of
ATP from dying tumor cells in the presence of the chemotherapeutic drugs. Besides the
inclusion of chemotherapy, one significant difference in this study was the addition of IL-12,
which bypasses the requirement for the Nlrp3 inflammasome. We have found IL-12 is
significantly generated by the DCs used by our group. Therefore, our findings suggest that
in the presence of IL-12, activation of the Nlrp3 inflammasome enhances the accumulation
of MDSCs and suppresses immune responses.
In summary, the expression of Nlrp3 in the tumor microenvironment diminishes antitumor
immunity and vaccine efficacy by facilitating the migration of MDSCs to the site of the
tumor. Since MDSCs express Nlrp3, their influx becomes part of a positive feedback loop
leading to further expansion of these cells. These findings suggest novel means of increasing
the effectiveness of DC vaccines by targeting the Nlrp3 inflammasome.
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Figure 1. Nlrp3 is expressed by tumor-associated myeloid cells
Expression of Nlrp3 by real time PCR in (1) Gr-1+, CD11b+ (2) Gr-1−, CD11b+ and (3)
Gr-1−, CD11b− sorted cells. The panel on left is a representative dot plot of sorted cells
from a subcutaneous B16-F10 tumor in a vaccinated WT (A) and Nlrp3−/− mouse (B). The
panel on the right is a bar graph of Nlrp3 transcripts normalized to cell number.
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Figure 2. DC vaccine improves survival in Nlrp3−/− mice but not WT mice
(A) Survival curves of WT and Nlrp3−/− mice after receiving a subcutaneous injection with
1×104 B16-F10 melanoma cells. (B) Survival of Nlrp3−/− mice was significantly improved
after receiving 1×106 tumor-lysate pulsed DCs (DC Vx) on day 3 and 10 after tumor
injection. No improvement was seen in WT mice. (C) Nlrp3−/− mice show improved
survival after receiving vaccines from either Nlrp3−/− or WT mice. (D) WT mice show no
improvement in survival after receiving vaccines from WT or Nlrp3−/− mice.
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Figure 3. Vaccinated Nlrp3−/− mice demonstrate greater CD8+ T cell response
(A) Survival curves of vaccinated (Vx) or naive Nlrp3−/− mice after rechallenge with B16-
F10 or Lewis Lung cancer (LLCa) cells. (B) Survival of vaccinated Nlrp3−/− mice following
depletion of CD8+, CD4+, and NK cells. (C) The graph shows the hazard ratio and
confidence intervals that compare survival of cell depleted Nlrp3−/− with control Nlrp3−/−
mice. Values greater than 1 (to the left) demonstrate decreased survival compared to
untreated Nlrp3−/− mice. (D) Total number of CD4+ and CD8+ effector cells from DC
vaccinated Nlrp3−/− (black) and WT (gray) mice. Palpable tumors (gray) were defined by a
measurable difference (> 0.2 mm) between the right and left leg; non-palpable tumors were
grossly identifiable during dissection.
van Deventer et al. Page 14













Figure 4. WT and Nlrp3−/− MDSCs have a similar microscopic appearance and suppressive
capacity
(A) Flow cytometry dot plots for tumor-associated cells isolated from vaccinated WT and
Nlrp3−/− mice. Cells were sorted by the gates shown and then examined after cytospin with
Wright Giemsa staining. Lens magnification is 500X; scale bar is 20 μm. (B) Line graph
showing suppression of a MLR reaction by granulocytic (solid line) and monocytic (dashed
line) MDSCs from WT (squares) and Nlrp3−/− (diamonds) mice. Significance was
determined by comparing proliferation with control MLR response (dotted line). Results are
averaged from three separate experiments.
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Figure 5. Superior response to DC vaccines by Nlrp3−/− mice is due to impaired migration of
MDSCs
(A) Percentages of MDSCs from the spleen and total number of MDSCs in the TDLN of
WT (striped) and Nlrp3−/− (solid) mice as determined by flow cytometry 14 days after
tumor injection. (B) The total number of tumor-associated Gr-1+, CD11b+ cells is increased
in WT mice as determined by microscopy. (C) Increased percentage of monocytic MDSCs
(left) and granulocytic MDSCs (right) from the tumor of WT (striped) compared to Nlrp3−/−
(solid) mice as determined by flow cytometry. (D) Survival curves of WT and Nlrp3−/−
mice treated with anti-Gr-1 antibody (dotted arrows) and DC vaccine (solid arrows). (E)
Contour plots on the left show phenotype of MDSCs isolated from the spleens of WT
(upper) and Nlrp3−/− (lower) mice prior to injection into Nlrp3−/− mice. Dot plots on the
right show cells recovered from B16 tumors in vaccinated Nlrp3−/− mice. Upper panels are
WT EGFP+ MDSCs and lower panels are Nlrp3−/− EGFP+ MDSCs. Values represent the
average number of cells recovered from each tumor.
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